<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82423">
  <stage>Registered</stage>
  <submitdate>16/11/2007</submitdate>
  <approvaldate>22/11/2007</approvaldate>
  <actrnumber>ACTRN12607000603415</actrnumber>
  <trial_identification>
    <studytitle>Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer?</studytitle>
    <scientifictitle>Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer?</scientifictitle>
    <utrn />
    <trialacronym>Symptom Benefit</trialacronym>
    <secondaryid>Australia and New Zealand Gynecological Oncology Group: ANZGOG-0701</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Women who have platinum resistant/refractory epithelial ovarian cancer with a life expectancy &gt; 3 months who are about to start palliative chemotherapy.</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All patients will fill out a number of health realted quality of life (HRQL) questionnaires prior to, during, and after receiving palliative chemotherapy.</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Stage 1: 
To determine the symptoms and aspects of HRQL that are rated most severe, troublesome and important by women with platinum resistant/refractory ovarian cancer.</outcome>
      <timepoint>Assessed using quality of life questionnaires; before, during, and at end of standard care. During a period of 12-16 weeks treatment, assessment would be prior to each treatment cycle. Since the standard treatment timeframe cannot be specified beforehand, a window of 12-16 weeks has been stated. The questions will be asked at the beginning of a new treatment cycle (probably weekly or 2 weekly and so on).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Stage 2: 
To determine the proportion of women benefiting from palliative chemotherapy as defined by a clinically significant improvement in HRQL scores and improvement of symptoms. 
To develop a better measure of benefit of palliative chemotherapy than using objective response rate alone.</outcome>
      <timepoint>Assessed using quality of life questionnaires; before, during, and at end of standard care. During a period of 12-16 weeks treatment, assessment would be prior to each treatment cycle. Since the standard treatment timeframe cannot be specified beforehand, a window of 12-16 weeks has been stated. The questions will be asked at the beginning of a new treatment cycle (three to four weekly).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>N/A</outcome>
      <timepoint>N/A</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>*Age &gt;= 18 years
*Histologically confirmed ovarian cancer/primary peritoneal cancer
* Recurrent / progressive disease measured by Cancer Antigen 125 (CA125), radiological or clinical)
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-3
* Life Expectancy &gt; 3 months
* Able to commence treatment within 2 weeks of enrollment
* Sufficient English to complete questionnaires independently in the stage 1 component which will be carried out in selected centers in Australia and New Zealand and Canada</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Any condition that compromises the patients ability to give informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Psychosocial</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/02/2008</anticipatedstartdate>
    <actualstartdate>28/02/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>10/10/2014</actualenddate>
    <samplesize>650</samplesize>
    <actualsamplesize>948</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/12/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,TAS,VIC</recruitmentstate>
    <postcode>2031</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Unknown at this stage</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Unknown at this stage</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Unknown at this stage</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Not applicable</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Unknown at this stage</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>ANZGOG Co-operative Research Group</primarysponsorname>
    <primarysponsoraddress>Locked Bag 77
Camperdown NSW 1450</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>ANZGOG Coperative Research Group</fundingname>
      <fundingaddress>Locked Bag 77
Camperdown NSW 1450</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council - Clinical Trial Centre</fundingname>
      <fundingaddress>Locked Bag 77
Camperdown NSW 1450</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Psycho-Oncology Cooperative Research Group (PoCoG)</sponsorname>
      <sponsoraddress>School of Psychology
Brennan MacCallum Building (A18)
University of Sydney
NSW 2006</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Princess Margaret Hospital</othercollaboratorname>
      <othercollaboratoraddress>610 University Ave
Toronto</othercollaboratoraddress>
      <othercollaboratorcountry>Canada</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In this research project we will study quality of life issues related to having advanced ovarian cancer and undergoing chemotherapy. We are interested in knowing how women are doing during chemotherapy for ovarian cancer and whether symptom improvement occurs with treatment.</summary>
    <trialwebsite />
    <publication>There are no publications up to date. The statistics team is performing the analysis at the moment</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Cancer Institute of NSW</ethicname>
      <ethicaddress>Level 1
Biomedical Building
Australian Technology Park
1 Central Avenue (off Garden Road)
Eveleigh NSW 2015</ethicaddress>
      <ethicapprovaldate>20/12/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>3/10/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney Local Health District Human Research Ethics Committee</ethicname>
      <ethicaddress>Suite 210, RPA Medical Centre</ethicaddress>
      <ethicapprovaldate>18/10/2013</ethicapprovaldate>
      <hrec>X13-0172&amp;HREC/13/RPAH/272</hrec>
      <ethicsubmitdate>25/09/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Michael Friedlander </name>
      <address>National Health and Medical Research Council - Clinical Trial Centre (NHMRC CTC)
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 93822606 </phone>
      <fax>+61 2 93822588 </fax>
      <email>m.friedlander@unsw.edu.au </email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Prof Michael Friedlander</name>
      <address>Oncology Day Centre
Prince of Wales Hospital
Randwick NSW 2031</address>
      <phone>+61 2 93822606</phone>
      <fax>+61 2 93822588</fax>
      <email>m.friedlander@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kim Gillies</name>
      <address>NHMRC Clinical Trial Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+ 61 2 95625032</phone>
      <fax>+61 2 95625094</fax>
      <email>symptombenefit@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Michael Friedlander</name>
      <address>Oncology Day Centre Prince of Wales Hospital Randwick NSW 2031 </address>
      <phone>+61 2 93822606 </phone>
      <fax />
      <email>m.friedlander@unsw.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>